OUR MISSION: Our mission is to become a leader in the discovery and development of next generation antibodies for the treatment of cancer and other diseases with unmet medical need.
Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The Company's powerful research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong,
broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allows Affimed to identify antibodies against even the most difficult of targets. Affimed's proprietary antibody formats include 'TandAbs™', unique tetravalent
antibodies that are particularly well suited to targeting tumor cells. Affimed's two most advanced therapeutic programs, in late preclinical development, comprise TandAbs™ leads in Non-Hodgkin's Lymphoma and Hodgkin's Disease. Affimed is based in Heidelberg, Germany.
-----------------------------------------------------------------------------------------------------------------------------------
Click here to download the latest article from JMB
------------------------------------------------------------------------------------------------------------------------------------